{"id":"W4417530891","doi":"10.1016/j.esmorc.2025.100116","title":"THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN CHONDROSARCOMA: RESULTS FROM THE RANDOMIZED, REGISTRATIONAL, PHASE 2 CHONDRAGON STUDY","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Bone Tumor Diagnosis and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Institute of Cancer Research","funders":"University of Colorado School of Medicine, Anschutz Medical Campus; European Network for Rare Adult Solid Cancers; Feinberg School of Medicine; Centre Léon Bérard; Universitair Medisch Centrum Groningen; Cleveland Clinic; University College London; Institut Gustave-Roussy; Vanderbilt University; Moffitt Cancer Center; Universiteit Leiden; Leids Universitair Medisch Centrum; University of California, San Francisco; Vanderbilt University Medical Center; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Johns Hopkins University; University of Texas MD Anderson Cancer Center; Northwestern University; Vanderbilt-Ingram Cancer Center; Memorial Sloan-Kettering Cancer Center","keywords":"Agonist; Placebo; Clinical trial; Receptor; Phase (matter)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009564976,0.0007704418,0.001208538,0.0002316813,0.0001894277,0.0006272562,0.000549696,0.0007295541,0.002511831],"category_scores_gemma":[0.0006786146,0.0002375857,0.000879248,0.0002949009,0.0004748099,0.000513589,0.000213239,0.00130878,0.0004655613],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005408481,"about_ca_system_score_gemma":0.0006482577,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001191873,"about_ca_topic_score_gemma":0.003752395,"domain_scores_codex":[0.999657,0.0001802424,0.0000211538,0.00003576924,0.00004559363,0.0000600924],"domain_scores_gemma":[0.9997003,0.0000711126,0.000100066,0.00003201548,0.00002509996,0.00007136873],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8466896,0.00999412,0.002572408,0.001726562,0.002630483,0.00008476347,0.0001181067,0.001316998,0.01591852,0.0004290214,0.003894688,0.1146248],"study_design_scores_gemma":[0.8028005,0.1732344,0.013544,0.0001271305,0.002185375,0.0002148257,0.0001258471,0.001062651,0.002733342,0.0003507065,0.003584719,0.00003665781],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849835,0.01030892,0.0004569522,0.0004654851,0.0001820182,0.0006570307,0.000787611,0.00008863509,0.00206988],"genre_scores_gemma":[0.988358,0.00610589,0.0006348179,0.0006554947,0.0001370099,0.000550237,0.00142616,0.0000241153,0.002108438],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002511831,"threshold_uncertainty_score":0.008402884,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02316641315826398,"score_gpt":0.3242507285497494,"score_spread":0.3010843153914854,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}